AstraZeneca CEO Pascal Soriot said the U.K.-listed company had many reasons to be in the U.S., adding that it was “rapidly ...

Merck & Co on Tuesday announced job and cost cuts that it said will save $3 billion a year, after it posted lower ...

According to the latest study from BCC Research, "Biologic Therapeutic Drugs: Technologies and Global Markets" is projected ...

Shares of GSK fell to below $30 around the time of the demerger, but have since recovered to about $36. The 20% gain over 34 ...

Discover how Genome Valley is emerging as an essential partner in global biopharma and how it is now venturing into cell and ...

Market OutlineThe Global Pharmaceutical Manufacturing Market is valued at USD 576.54 Billion in 2024 and is projected to ...

Nissan is closing its Oppama factory to reduce costs and will move production to Kyushu. The closure is part of a restructuring effort to boost profitability. The company has been financially strained ...

FDA accepts GSK's filing to extend Arexvy's RSV vaccine use to high-risk adults under 50, with a decision due in 2026.

British drugmaker GSK said on Monday it had submitted an application to the U.S. Food and Drug Administration to extend the use of its respiratory syncytial virus (RSV) vaccine to adults under the ...

GSK's vaccine is currently approved in the U.S. for preventing RSV-related disease in adults aged 60 and above, and in at-risk adults aged 50 to 59.

If approved in the world's biggest pharmaceuticals market, GSK's vaccine, Arexvy, would be competing for a market share in the 18-49 age group with Moderna's mRESVIA and Pfizer's Abrysvo. RSV is a ...

Developing reliable, generalized, and accurate defect detection technology for photovoltaic (PV) manufacturers is particularly critical with the demand for production line expansion. Existing ...